HLA-A*2402 & B2M & EBV BRLF1 (TYPVLEEMF)

HLA-A*2402 & B2M & EBV BRLF1 (TYPVLEEMF) Produktliste

Attribut
Protein (1)
Produktbibliothek
Online (1)
Spezies
Human (1)
Etikett
His Tag & Avi Tag (1)
Marker
Unconjugated (1)

Produktnummer	Spezies	Expressionssystem	Produktbeschreibung	Proteinstruktur	Reinheit	Eigenschaften	Vorbestellen/Bestellen
HLF-H52E5	Human	HEK293	Unconjugated Human HLA-A*24:02&B2M&EBV BRLF1 (TYPVLEEMF) Complex Protein (Monomer, MALS verified)				In den Warenkorb legen

Gesamtmenge1

HLA-A*2402 & B2M & EBV BRLF1 (TYPVLEEMF) Molekülhintergrund

This is a recombinant protein complex of HLA-A*24:02 presenting an immunodominant 9-mer peptide (TYPVLEEMF) derived from the Epstein-Barr virus (EBV) immediate-early transactivator BRLF1. HLA-A*24:02 is a common class I allele, and this peptide is a well-characterized target for CD8⁺ T cells in EBV-seropositive individuals, making the complex a valuable tool for studying antigen-specific T cell responses in viral immunity and immunotherapies.

Klinische Arzneimittelinformation

Englischer Name	Forschungscode	Forschungsphase	Firma	Indikationen	Klinische Studie
CHM-2101	CDH17-CAR T; CHM-2101; CHM2101; CHM-2101 CAR-T cells	Phase 2 Clinical	University Of Pennsylvania	Stomach Neoplasms; Pancreatic Neoplasms; Neuroendocrine Tumors; Colorectal Neoplasms; Gastrointestinal Neoplasms	Details
BI-905711	BI-905711	Phase 1 Clinical	Boehringer Ingelheim Gmbh	Pancreatic Neoplasms; Cholangiocarcinoma; Gastrointestinal Neoplasms	Details
ARB-202	ARB-202	Phase 1 Clinical	Arbele Corp	Liver Neoplasms; Biliary Tract Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms; Cholangiocarcinoma; Colorectal Neoplasms; Esophageal adenocarcinoma; Gastrointestinal Neoplasms	Details